Glyxambi tablets now available in the U.S.

Glyxambi (empagliflozin/linagliptin) tablets are now available by prescription in the U.S. The product, part of the Boehringer Ingelheim Pharmaceuticals and Eli Lilly Diabetes alliance portfolio, is the first and only dual inhibitor combination therapy approved in the U.S. to combine the mechanisms of action of a sodium/glucose cotransporter 2 (SGLT2) inhibitor and a dipeptidyl peptidase 4 (DPP-IV) inhibitor in a once-daily tablet.

It is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when both empagliflozin and linagliptin are appropriate treatments (Boehringer Ingelheim Pharmaceuticals News Release).